Better use of immune checkpoint inhibition: Treating higher risk patients and examining neurologic toxicity

M A Postow^{1

2}

Affiliations

¹ Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
² Department of Medicine, Weill Cornell Medical College, New York, USA.

Free article

Editorial

M A Postow. Ann Oncol. 2017.

Free article

. 2017 Feb 1;28(2):204-205.

doi: 10.1093/annonc/mdw642.

M A Postow^{1

2}

¹ Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
² Department of Medicine, Weill Cornell Medical College, New York, USA.

No abstract available

Comment on

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Menzies AM, et al. Ann Oncol. 2017 Feb 1;28(2):368-376. doi: 10.1093/annonc/mdw443. Ann Oncol. 2017. PMID: 27687304 Free PMC article.
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.
Spain L, Walls G, Julve M, O'Meara K, Schmid T, Kalaitzaki E, Turajlic S, Gore M, Rees J, Larkin J. Spain L, et al. Ann Oncol. 2017 Feb 1;28(2):377-385. doi: 10.1093/annonc/mdw558. Ann Oncol. 2017. PMID: 28426103 Review.